No Data
No Data
Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Insider Sale: CEO & President of $SPRO Sells 106,408 Shares
The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts
H.C. Wainwright Maintains Spero Therapeutics(SPRO.US) With Buy Rating, Maintains Target Price $5
Express News | HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $5 Price Target